Baxalta To Showcase Innovation Leadership In Primary Immune Deficiencies During 2016 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting

• Presentations to highlight scientific updates on investigational Human Immune Globulin Subcutaneous, 20% (IGSC 20%) and HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]
• Baxalta continues to build its leadership in the primary immunodeficiency (PI) community by developing and expanding access to innovative treatments with the goal of reducing burden for patients globally

BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, will present data highlighting its commitment to innovation in primary immunodeficiencies (PI) at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, March 4 – 7, 2016 in Los Angeles, California.

''Our presence at the 2016 AAAAI annual meeting is a testament of our continual commitment to research and our progress in developing and expanding access to treatments for patients with primary immunodeficiencies,'' said John Davis, M.D., M.P.H., vice president, Clinical Research and global therapeutic area head, Immunology, Baxalta. ''Baxalta is committed to building on our leadership in the PI community, with the goal of reducing the burden for patients worldwide.''

Researchers from Baxalta will present scientific updates on the company’s investigational treatment, Human Immune Globulin Subcutaneous, 20% (IGSC 20%). This is the first presentation of the full data set from the North American Phase 2/3 study. IGSC 20% is currently under regulatory review in the United States and in Europe with a decision expected later this year. The following abstract was accepted for a poster presentation:

• Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients With Primary Immunodeficiency Disease (PIDD) in North America. Session 4203: Primary Immunodeficiency. Poster 721. Monday, March 7, 9:45 a.m. – 10:45 a.m., in Convention Center, Level One, South Exhibit Hall H.

In addition, researchers will present real-world experience and long-term safety data with HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] following the FDA and European regulatory approvals. Abstracts accepted for poster presentations include:

• Real-World Use of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IG) (IGHy) in Patients with Primary Immunodeficiency Disorders (PIDD). Session 4203: Primary Immunodeficiency. Poster 718. Monday, March 7, 9:45 a.m. – 10:45 a.m., in Convention Center, Level One, South Exhibit Hall H.
• Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections Over Time. Session 4203: Primary Immunodeficiency. Poster 714. Monday, March 7, 9:45 a.m. – 10:45 a.m., in Convention Center, Level One, South Exhibit Hall H.
• Local Adverse Reaction Rates Decreased Over Time During Treatment With Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients With Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies. Session 4203: Primary Immunodeficiency. Poster 716. Monday, March 7, 9:45 a.m. – 10:45 a.m., in Convention Center, Level One, South Exhibit Hall H.

About Primary Immunodeficiency

Primary immunodeficiencies (PI) are a group of nearly 300 disorders in which part of the body's immune system is missing or does not function properly.¹ Normally, the immune system protects the body from pathogenic microorganisms like bacteria, viruses, and fungi, which can cause infectious diseases. When any part of a person's immune system is absent or dysfunctional, they are susceptible to infections and may take longer to recover from infections. When a defect in the immune system is inherited, it is called primary immune deficiency.² It is estimated that as many as six million children and adults may be affected by PI worldwide.³

About HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Indication and Usage

HYQVIA is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of Primary Immunodeficiency (PI) in adults. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Limitation of Use:

Safety and efficacy of chronic use of recombinant human hyaluronidase in HYQVIA have not been established in conditions other than PI.

Detailed Important Risk Information

BOXED WARNING: THROMBOSIS

Thrombosis may occur with immune globulin products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

CONTRAINDICATIONS

HYQVIA is contraindicated: in patients who have a history of anaphylactic or severe systemic hypersensitivity reactions to the administration of Human Immune Globulin (IgG); in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity; and in patients with known systemic hypersensitivity to hyaluronidase or Recombinant Human Hyaluronidase of HYQVIA.

WARNINGS and PRECAUTIONS

Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with IgG. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

Thrombosis: Thrombosis may occur following treatment with immune globulin products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.

Immunogenicity of Recombinant Human Hyaluronidase (PH20): Non-neutralizing antibodies to the recombinant human hyaluronidase component can develop. The potential exists for such antibodies to cross-react with endogenous PH20, which is known to be expressed in adult male testes, epididymis, and sperm. The clinical significance of these antibodies or whether they interfere with fertilization in humans is unknown.

Aseptic Meningitis Syndrome (AMS): AMS has been reported to occur with IgG treatment administered intravenously and subcutaneously. Discontinuation of IgG treatment has resulted in remission of AMS within several days without sequelae.

Hemolysis: Acute intravascular hemolysis has been reported following intravenously administered IgG products, including Immune Globulin Infusion 10% (Human) administered intravenously, and delayed hemolytic anemia can develop due to enhanced RBC sequestration. IgG products, including HYQVIA, contain blood group antibodies which may cause a positive direct antiglobulin reaction and hemolysis.

Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur upon use of IgG products administered intravenously, especially those containing sucrose. HYQVIA does not contain sucrose. Ensure that patients are not volume depleted prior to the initiation of infusion of HYQVIA. Monitor renal function and urine output and consider lower, more frequent dosing in patients who are at risk of developing renal dysfunction because of pre-existing renal insufficiency or predisposition to acute renal failure.

Spread of Localized Infection: Do not infuse HYQVIA into or around an infected or acutely inflamed area due to potential risk of spreading a localized infection.

Transfusion-Related Acute Lung Injury (TRALI): Non-cardiogenic pulmonary edema has been reported in patients following treatment with intravenously administered IgG products, including Immune Globulin Infusion 10% (Human). TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever.

Transmittable Infectious agents: Because the Immune Globulin Infusion 10% (Human) of HYQVIA is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses and other pathogens, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of viral transmission or CJD have been associated with HYQVIA.

Interference with Laboratory Tests: False positive serological test results, with the potential for misleading interpretation, may result from the transitory rise of the various passively transferred antibodies in the patient’s blood after infusion of IgG. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test.

ADVERSE REACTIONS

The most common adverse reactions observed in > 5% of patients in the clinical trials were: local adverse reactions (52%), headache (21%), antibody formation against recombinant human hyaluronidase (18%), fatigue (11%), nausea (7%), pyrexia (7%), and vomiting (7%). No serious adverse reactions occurred during the HYQVIA clinical trials.

Please see the Full Prescribing Information, including Boxed Warning for HYQVIA at:
http://baxalta.com/assets/documents/HYQVIA_PI.pdf.

For more information, learn more about HYQVIA at www.HYQVIA.com.

About Baxalta

Baxalta Incorporated (NYSE: BXLT) is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology and oncology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, with its Global Innovation Center in Cambridge, Mass., Baxalta employs 17,000 employees worldwide.

Forward-Looking Statements

This release includes forward-looking statements concerning Baxalta's treatments for PI, including expectations with regard to regulatory filings and potential impact on patients. Such statements are made of the date that they were first issued and are based on current expectations, beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Baxalta's control and which could cause actual results to differ materially from those in the forward-looking statements, including the following: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; product quality, manufacturing or supply issues; patient safety issues; and other risks identified in Baxalta's filings with the Securities and Exchange Commission, all of which are available on Baxalta's website. Baxalta expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

References

1. Bousfiha A, Jeddane I, Al-Herz W, et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015; 35(8): 727-738.

2. Blaese RM, Bonilla FA, Stiehm ER, Younger ME, eds. Patient & Family Handbook for Primary Immunodeficiency Diseases. 5th ed. Towson, MD: Immune Deficiency Foundation; 2013.

3. Bousfiha AA et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013 Jan;33(1):1-7.